Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid
On Monday, as Incyte’s stock price $INCY headed south in the wake of the FDA’s surprising decision to boot back baricitinib, the biotech was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
